Literature DB >> 9430303

Use of botulinum A toxin in patients at risk of wound complications following eyelid reconstruction.

J C Choi1, M J Lucarelli, J W Shore.   

Abstract

Our purpose was to determine the efficacy of botulinum A toxin (BOTOX) in promoting wound immobilization and preventing wound dehiscence in patients at risk of wound-healing complications following eyelid reconstruction. In 11 patients at risk of postoperative wound complications, we injected BOTOX into the periocular musculature in addition to standard suture tarsorrhaphy. Each patient experienced excellent wound immobilization and wound healing. There were no complications. Adjuvant use of BOTOX, in conjunction with suture tarsorrhaphy, immobilizes the eyelids and promotes wound healing in patients at risk of wound complications following eyelid reconstruction.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9430303     DOI: 10.1097/00002341-199712000-00006

Source DB:  PubMed          Journal:  Ophthalmic Plast Reconstr Surg        ISSN: 0740-9303            Impact factor:   1.746


  3 in total

1.  Personal Technique of Microinfiltration With Botulin Toxin: The SINB Technique (Superficial Injection Needling Botulinum).

Authors:  Francesco Calvani; Stefania Santini; Emanuele Bartoletti; Alessandra Alhadeff
Journal:  Plast Surg (Oakv)       Date:  2018-10-11       Impact factor: 0.947

2.  Evaluation of efficacy and safety of botulinum toxin type A injection in patients requiring temporary tarsorrhaphy to improve corneal epithelial defects.

Authors:  Abolfazl Kasaee; Mohammad Reza Musavi; Syed Ziaeddin Tabatabaie; Mohammad Nasser Hashemian; Shahrzad Mohebbi; Alireza Khodabandeh; Mohammad Taher Rajabi
Journal:  Int J Ophthalmol       Date:  2010-09-18       Impact factor: 1.779

3.  The Use of Botulinum Toxin-A as an Adjunctive Treatment for Facial Atrophic and Hypertrophic Scars After Surgical Correction.

Authors:  Anagha Samarth; Leelavathy Budamakuntla; Kanathur Shilpa
Journal:  J Cutan Aesthet Surg       Date:  2022 Apr-Jun
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.